November 20, 2023, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) trading session started at the price of $2.12, that was 1.47% jump from the session before. During the day, the shares moved up to $2.335 and dropped to $2.03 before settling in for the closing price of $2.04. A 52-week range for ARQT has been $1.80 – $19.10.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 34.35%. With a float of $77.27 million, this company’s outstanding shares have now reached $94.38 million.
Considering the fact that the conglomerate employs 268 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is +54.02, operating margin of -8183.04, and the pretax margin is -8449.76.
Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcutis Biotherapeutics Inc stocks. The insider ownership of Arcutis Biotherapeutics Inc is 18.13%, while institutional ownership is 70.40%. The most recent insider transaction that took place on Oct 24, was worth 200,000. In this transaction 10% Owner of this company bought 80,000 shares at a rate of $2.50, taking the stock ownership to the 8,764,232 shares. Before that another transaction happened on Aug 21, when Company’s insider sold 1,605 for $7.04, making the entire transaction worth $11,302. This insider now owns 58,357 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/29/2023, it has been observed that the corporation posted -$0.73 earnings per share (EPS) during the time that was better than consensus figure (set at -$0.86) by $0.13. This company achieved a net margin of -8449.76 while generating a return on equity of -122.80. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -110.36% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
You can see what Arcutis Biotherapeutics Inc (ARQT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 52.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.65, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -2.68 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Compared to the last year’s volume of 1.41 million, its volume of 3.21 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 32.65%. Additionally, its Average True Range was 0.32.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 2.82%, which indicates a significant decrease from 35.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.38% in the past 14 days, which was higher than the 89.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.90, while its 200-day Moving Average is $9.37. Nevertheless, the first resistance level for the watch stands at $2.26 in the near term. At $2.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.57. If the price goes on to break the first support level at $1.95, it is likely to go to the next support level at $1.84. Now, if the price goes above the second support level, the third support stands at $1.65.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are 94,382K outstanding shares of the company, which has a market capitalization of 195.37 million. As of now, sales total 3,690 K while income totals -311,460 K. Its latest quarter income was 38,110 K while its last quarter net income were -44,770 K.